1996
Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses.
Garfein R, Vlahov D, Galai N, Doherty M, Nelson K. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. American Journal Of Public Health 1996, 86: 655-661. PMID: 8629715, PMCID: PMC1380472, DOI: 10.2105/ajph.86.5.655.Peer-Reviewed Original ResearchConceptsHepatitis B virusHepatitis C virusViral infectionSeroprevalence of HCVBlood-borne viral infectionsHuman T-lymphotropic virus type IShort-term injectorsHuman immunodeficiency virusSexual risk reduction interventionInjection drug usersIllicit drug injectorsRisk reduction interventionsVirus type IHepatitis CHepatitis BHIV infectionImmunodeficiency virusPrimary preventionC virusB virusHuman immunodeficiencyDrug injectionSequential cohortsDrug injectorsLymphotropic virus
1991
Diagnosis and differentiation of HTLV-I and HTLV-II infection by enzyme immunoassays using synthetic peptides.
Viscidi R, Hill P, Li S, Cerny E, Vlahov D, Farzadegan H, Halsey N, Kelen G, Quinn T. Diagnosis and differentiation of HTLV-I and HTLV-II infection by enzyme immunoassays using synthetic peptides. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1991, 4: 1190-8. PMID: 1941526.Peer-Reviewed Original ResearchConceptsEnzyme immunoassayHTLV-IIAntibody reactivityPeptide enzyme immunoassayHTLV-II infectionEpidemiology of HTLVDifferentiation of HTLVMicrotiter plate enzyme immunoassaysPattern of reactivitySeronegative controlsEmergency departmentEnv peptidesPositive seraViral infectionNeurological diseasesHTLVSynthetic peptidesInfectionDrug abuseMajor envelope proteinEnvEnvelope proteinPatientsSerumAntibodies